Related Experiment Video

Updated: May 23, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene

Brandon L McClellan1,2, Jorge A Peña Agudelo1,2, Anzar A Mujeeb1,2

  • 1Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Molecular Therapy. Oncology
|May 22, 2026
PubMed

Insights

Mutant IDH1 gliomas have lower CD73 and adenosine levels. CD73 blockade combined with gene therapy shows promise for treating wild-type IDH1 gliomas by boosting anti-tumor T cell activity.

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Cancer epigenetics

Background:

  • Gliomas are primary malignant brain tumors, with many harboring mutant isocitrate dehydrogenase 1 (mIDH1).
  • Mutant IDH1 produces 2-hydroxyglutarate (2HG), reprogramming the tumor microenvironment (TME) and influencing immune responses.
  • Adenosine production by CD73 is an immunosuppressive mechanism within the glioma TME.

Purpose of the Study:

  • To investigate the impact of mIDH1 on CD73 expression and adenosine levels in gliomas.
  • To evaluate CD73 blockade as a potential immunotherapy target, particularly in wild-type IDH1 (wtIDH1) gliomas.

Main Methods:

  • Assessed CD73 expression and adenosine levels in mIDH1 and wtIDH1 glioma cells.
  • Utilized DNA methylation analysis to understand CD73 regulation.
  • Tested CD73 inhibition as monotherapy and in combination with Ad-TK and Ad-Flt3L gene therapy in wtIDH1 glioma mouse models.

Main Results:

  • mIDH1 glioma cells exhibited reduced CD73 expression due to DNA hypermethylation, leading to lower adenosine levels.
  • CD73 inhibition as monotherapy did not improve survival in wtIDH1 glioma-bearing mice.
  • Combination therapy (CD73 blockade with Ad-TK/Ad-Flt3L) significantly enhanced therapeutic efficacy and increased anti-glioma T cell activity.

Conclusions:

  • mIDH1 status influences CD73 expression and adenosine production in gliomas.
  • Combined CD73 blockade and immune-stimulatory gene therapy (Ad-TK/Ad-Flt3L) represents a promising, clinically translatable treatment strategy for wtIDH1 gliomas.
Keywords:
Ad-TK/Ad-Flt3LCD73MT: Regular Issuegene therapygliomaimmunotherapymutant IDH1

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...